Srijon K. Banerjee
Postdoctoral Research Fellow
Also affiliated: Bose Institute (2013–2022); University of Pittsburgh (2022–2024)
Postdoc Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Srijon K. Banerjee's research focuses on host-pathogen interactions and the molecular mechanisms underlying infectious diseases. He has investigated the role of bacterial proteins and host immune responses in various infections, including those caused by *Mycobacterium tuberculosis*, *Staphylococcus aureus*, and SARS-CoV-2.
His work has explored bacterial adaptation to environmental stresses, such as hypoxia and nitric oxide, and the contribution of DNA repair pathways and specialized transport systems to bacterial survival. Banerjee has also examined the host immune response, including the role of cytokines like Interleukin-17 and inflammasomes like NLRP3, in mediating inflammation and tissue damage during infections. He utilizes experimental platforms such as precision-cut lung slices to study disease pathogenesis and evaluate antiviral drug efficacy.
Banerjee is a Co-Principal Investigator on a $1,591,584 grant from the NIH/National Cancer Institute for "TCIA Sustainment and Scalability - Platforms for Quantitative Imaging Informatics in Precision Medicine." He has collaborated with researchers at the University of Arkansas for Medical Sciences, including Priyangi A. Malaviarachchi, Joshua L. Kennedy, Richard C. Kurten, and Duah Alkam, with whom he has co-authored multiple publications. His research output includes 18 publications and has garnered 475 citations, with an h-index of 10.
Metrics
- h-index: 10
- Publications: 18
- Citations: 481
Selected Publications
-
An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy (2024)
-
An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy (2023)
-
The Yersinia pestis GTPase BipA Promotes Pathogenesis of Primary Pneumonic Plague (2020)
-
A Dual Role for the Plasminogen Activator Protease During the Preinflammatory Phase of Primary Pneumonic Plague (2020)
-
Modeling Pneumonic Plague in Human Precision-Cut Lung Slices Highlights a Role for the Plasminogen Activator Protease in Facilitating Type 3 Secretion (2019)
Federal Grants 1 $1,591,584 total
Collaboration Network
Top Collaborators
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
Similar Researchers
Based on overlapping research topics